Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2009

Open Access 01-12-2009 | Research article

Severity of Giardiainfection associated with post-infectious fatigue and abdominal symptoms two years after

Authors: Kristine Mørch, Kurt Hanevik, Guri Rortveit, Knut-Arne Wensaas, Geir Egil Eide, Trygve Hausken, Nina Langeland

Published in: BMC Infectious Diseases | Issue 1/2009

Login to get access

Abstract

Background

A high rate of post-infectious fatigue and abdominal symptoms two years after a waterborne outbreak of giardiasis in Bergen, Norway in 2004 has previously been reported. The aim of this report was to identify risk factors associated with such manifestations.

Methods

All laboratory confirmed cases of giardiasis (n = 1262) during the outbreak in Bergen in 2004 received a postal questionnaire two years after. Degree of post-infectious abdominal symptoms and fatigue, as well as previous abdominal problems, was recorded. In the statistical analyses number of treatment courses, treatment refractory infection, delayed education and sick leave were used as indices of protracted and severe Giardia infection. Age, gender, previous abdominal problems and symptoms during infection were also analysed as possible risk factors. Simple and multiple ordinal logistic regression models were used for the analyses.

Results

The response rate was 81% (1017/1262), 64% were women and median age was 31 years (range 3-93), compared to 61% women and 30 years (range 2-93) among all 1262 cases. Factors in multiple regression analysis significantly associated with abdominal symptoms two years after infection were: More than one treatment course, treatment refractory infection, delayed education, bloating and female gender. Abdominal problems prior to Giardia infection were not associated with post-infectious abdominal symptoms. More than one treatment course, delayed education, sick leave more than 2 weeks, and malaise at the time of infection, were significantly associated with fatigue in the multiple regression analysis, as were increasing age and previous abdominal problems.

Conclusion

Protracted and severe giardiasis seemed to be a risk factor for post-infectious fatigue and abdominal symptoms two years after clearing the Giardia infection.
Literature
1.
Savioli L, Smith H, Thompson A: Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol. 2006, 22 (5): 203-208. 10.1016/j.pt.2006.02.015.CrossRefPubMed
2.
Gilman RH, Marquis GS, Miranda E, Vestegui M, Martinez H: Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community. Lancet. 1988, 1 (8581): 343-345. 10.1016/S0140-6736(88)91131-2.CrossRefPubMed
3.
Hill DRNT: Intestinal Flagellate and Ciliate Infections. 2006, Elsevier, 2: Second
4.
Rendtorff RC: The experimental transmission of human intestinal protozoan parasites. II. Giardia lamblia cysts given in capsules. Am J Hyg. 1954, 59 (2): 209-220.PubMed
5.
Farthing MJ: Giardiasis. Gastroenterol Clin North Am. 1996, 25 (3): 493-515. 10.1016/S0889-8553(05)70260-0.CrossRefPubMed
6.
Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM: Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet. 2002, 359 (9306): 564-571. 10.1016/S0140-6736(02)07744-9.CrossRefPubMed
7.
Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P: A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Public Health. 2006, 6: 141-10.1186/1471-2458-6-141.CrossRefPubMedPubMedCentral
8.
Morch K, Hanevik K, Rortveit G, Wensaas KA, Langeland N: High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis. Trans R Soc Trop Med Hyg. 2009, 103 (5): 530-532. 10.1016/j.trstmh.2009.01.010.CrossRefPubMed
9.
Robertson LJ, Forberg T, Hermansen L, Gjerde BK, Langeland N: Demographics of Giardia infections in Bergen, Norway, subsequent to a waterborne outbreak. Scand J Infect Dis. 2008, 40 (2): 189-192. 10.1080/00365540701558672.CrossRefPubMed
10.
Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB: Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003, 98 (6): 1309-1314. 10.1111/j.1572-0241.2003.07458.x.CrossRefPubMed
11.
Morch K, Hanevik K, Robertson LJ, Strand EA, Langeland N: Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect. 2008
12.
Kleinbaum DG, Klein M: Logistic Regression. 2005, Springer, 2
13.
Seet RC, Quek AM, Lim EC: Post-infectious fatigue syndrome in dengue infection. J Clin Virol. 2007, 38 (1): 1-6. 10.1016/j.jcv.2006.10.011.CrossRefPubMed
14.
Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A: Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Bmj. 2006, 333 (7568): 575-10.1136/bmj.38933.585764.AE.CrossRefPubMedPubMedCentral
15.
White PD, Grover SA, Kangro HO, Thomas JM, Amess J, Clare AW: The validity and reliability of the fatigue syndrome that follows glandular fever. Psychol Med. 1995, 25 (5): 917-924. 10.1017/S0033291700037405.CrossRefPubMed
16.
Harley D, Bossingham D, Purdie DM, Pandeya N, Sleigh AC: Ross River virus disease in tropical Queensland: evolution of rheumatic manifestations in an inception cohort followed for six months. Med J Aust. 2002, 177 (7): 352-355.PubMed
17.
Hanevik K, Dizdar V, Langeland N, Hausken T: Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009, 9: 27-10.1186/1471-230X-9-27.CrossRefPubMedPubMedCentral
18.
Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC: Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis. 2001, 184 (5): 606-609. 10.1086/322845.CrossRefPubMed
19.
Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003, 125 (6): 1651-1659. 10.1053/j.gastro.2003.09.028.CrossRefPubMed
20.
Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM: Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006, 131 (2): 445-450. 10.1053/j.gastro.2006.05.053.CrossRefPubMed
21.
McKendrick MW, Read NW: Irritable bowel syndrome--post salmonella infection. J Infect. 1994, 29 (1): 1-3. 10.1016/S0163-4453(94)94871-2.CrossRefPubMed
22.
McKendrick MW: Post Salmonella irritable bowel syndrome--5 year review. J Infect. 1996, 32 (2): 170-171. 10.1016/S0163-4453(96)91715-6.CrossRefPubMed
23.
Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, Perona M: Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005, 129 (1): 98-104. 10.1053/j.gastro.2005.04.012.CrossRefPubMed
24.
Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004, 53 (8): 1096-1101. 10.1136/gut.2003.021154.CrossRefPubMedPubMedCentral
25.
Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI: Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol. 2005, 20 (3): 381-386. 10.1111/j.1440-1746.2005.03574.x.CrossRefPubMed
26.
Kim HS, Kim MS, Ji SW, Park H: [The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study]. Korean J Gastroenterol. 2006, 47 (4): 300-305.PubMed
27.
Soyturk M, Akpinar H, Gurler O, Pozio E, Sari I, Akar S, Akarsu M, Birlik M, Onen F, Akkoc N: Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol. 2007, 102 (5): 1064-1069. 10.1111/j.1572-0241.2007.01084.x.CrossRefPubMed
28.
Spiller RC: Role of infection in irritable bowel syndrome. J Gastroenterol. 2007, 42 (Suppl 17): 41-47. 10.1007/s00535-006-1925-8.CrossRefPubMed
29.
Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Bmj. 1997, 314 (7083): 779-782.CrossRefPubMedPubMedCentral
30.
Halvorson HA, Schlett CD, Riddle MS: Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol. 2006, 101 (8): 1894-1899. 10.1111/j.1572-0241.2006.00654.x. quiz 1942CrossRefPubMed
31.
Hanevik K, Hausken T, Morken MH, Strand EA, Morch K, Coll P, Helgeland L, Langeland N: Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect. 2007
32.
Muller N, von Allmen N: Recent insights into the mucosal reactions associated with Giardia lamblia infections. Int J Parasitol. 2005, 35 (13): 1339-1347. 10.1016/j.ijpara.2005.07.008.CrossRefPubMed
33.
Oberhuber G, Kastner N, Stolte M: Giardiasis: a histologic analysis of 567 cases. Scand J Gastroenterol. 1997, 32 (1): 48-51. 10.3109/00365529709025062.CrossRefPubMed
34.
Spiller R, Campbell E: Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 2006, 22 (1): 13-17. 10.1097/01.mog.0000194792.36466.5c.CrossRefPubMed
35.
Homan WL, Mank TG: Human giardiasis: genotype linked differences in clinical symptomatology. Int J Parasitol. 2001, 31 (8): 822-826. 10.1016/S0020-7519(01)00183-7.CrossRefPubMed
36.
Sahagun J, Clavel A, Goni P, Seral C, Llorente MT, Castillo FJ, Capilla S, Arias A, Gomez-Lus R: Correlation between the presence of symptoms and the Giardia duodenalis genotype. Eur J Clin Microbiol Infect Dis. 2008, 27 (1): 81-83. 10.1007/s10096-007-0404-3.CrossRefPubMed
37.
Gelanew T, Lalle M, Hailu A, Pozio E, Caccio SM: Molecular characterization of human isolates of Giardia duodenalis from Ethiopia. Acta Trop. 2007, 102 (2): 92-99. 10.1016/j.actatropica.2007.04.003.CrossRefPubMed
38.
Read C, Walters J, Robertson ID, Thompson RC: Correlation between genotype of Giardia duodenalis and diarrhoea. Int J Parasitol. 2002, 32 (2): 229-231. 10.1016/S0020-7519(01)00340-X.CrossRefPubMed
39.
Robertson LJ, Hermansen L, Gjerde BK, Strand E, Alvsvag JO, Langeland N: Application of genotyping during an extensive outbreak of waterborne giardiasis in Bergen, Norway, during autumn and winter 2004. Appl Environ Microbiol. 2006, 72 (3): 2212-2217. 10.1128/AEM.72.3.2212-2217.2006.CrossRefPubMedPubMedCentral
40.
Robertson LJ, Gjerde B: Occurrence of Cryptosporidium oocysts and Giardia cysts in raw waters in Norway. Scand J Public Health. 2001, 29 (3): 200-207. 10.1177/14034948010290030901.CrossRefPubMed
41.
Robertson LJ, Forberg T, Hermansen L, Gjerde BK, Langeland N: Molecular characterisation of Giardia isolates from clinical infections following a waterborne outbreak. J Infect. 2007, 55 (1): 79-88. 10.1016/j.jinf.2007.02.001.CrossRefPubMed
42.
Loge JH, Ekeberg O, Kaasa S: Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res. 1998, 45 (1 Spec No): 53-65. 10.1016/S0022-3999(97)00291-2.CrossRefPubMed
43.
Dunlop SP, Jenkins D, Spiller RC: Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol. 2004, 16 (10): 1011-1015. 10.1097/00042737-200410000-00010.CrossRefPubMed
44.
Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, Stewart JA, Abbey S, Jones JF, Gantz N, et al: Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003, 163 (13): 1530-1536. 10.1001/archinte.163.13.1530.CrossRefPubMed
45.
Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF, Plioplys S: A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999, 159 (18): 2129-2137. 10.1001/archinte.159.18.2129.CrossRefPubMed
46.
Prins JB, Meer van der JW, Bleijenberg G: Chronic fatigue syndrome. Lancet. 2006, 367 (9507): 346-355. 10.1016/S0140-6736(06)68073-2.CrossRefPubMed
47.
Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999, 44 (3): 400-406.CrossRefPubMedPubMedCentral
48.
Stark D, van Hal S, Marriott D, Ellis J, Harkness J: Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol. 2007, 37 (1): 11-20. 10.1016/j.ijpara.2006.09.009.CrossRefPubMed
49.
Grazioli B, Matera G, Laratta C, Schipani G, Guarnieri G, Spiniello E, Imeneo M, Amorosi A, Foca A, Luzza F: Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study. World J Gastroenterol. 2006, 12 (12): 1941-1944.CrossRefPubMedPubMedCentral
50.
Horman A, Korpela H, Sutinen J, Wedel H, Hanninen ML: Meta-analysis in assessment of the prevalence and annual incidence of Giardia spp. and Cryptosporidium spp. infections in humans in the Nordic countries. Int J Parasitol. 2004, 34 (12): 1337-1346. 10.1016/j.ijpara.2004.08.009.CrossRefPubMed
51.
Hanevik K, Morch K, Eide GE, Langeland N, Hausken T: Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: a randomized open clinical trial. Scand J Infect Dis. 2008, 40 (6-7): 517-522. 10.1080/00365540701827481.CrossRefPubMed
Metadata
Title
Severity of Giardiainfection associated with post-infectious fatigue and abdominal symptoms two years after
Authors
Kristine Mørch
Kurt Hanevik
Guri Rortveit
Knut-Arne Wensaas
Geir Egil Eide
Trygve Hausken
Nina Langeland
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2009
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-9-206

Other articles of this Issue 1/2009

BMC Infectious Diseases 1/2009 Go to the issue

Research article

New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response

Research article

Quarantine for pandemic influenza control at the borders of small island nations

Research article

Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay

Technical advance

Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases

Research article

Modulations of cell cycle checkpoints during HCV associated disease

Research article

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits